Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Penumbra (PEN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tr ...

Have you been paying attention to shares of Globus Medical (GMED) ? Shares have been on the move with the stock up 16.2% over the past month. The stock hit a new 52-week high of $65.74 in the previous session. Globus Medical has gained 15.8% since the start of the year compared to the 3.1% move for the Zacks Medical sector and the 4.9% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ear ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

Globus Medical, Inc. (GMED) reported adjusted earnings per share (EPS) of 72 cents in the first quarter of 2024, which beat the Zacks Consensus Estimate by 30.9%. The metric increased 35.8% year over year.The adjusted EPS excludes certain non-recurring expenses and benefits like the amortization of intangibles, acquisition-related costs/licensing and provision for litigation, among others.Without adjustments, the company registered a GAAP diluted loss of 5 cents compared with the year-ago EPS of 48 cents.Re ...

Globus Medical, Inc. (NYSE:GMED) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Brian Kearns - Senior Vice President, Business Development and Investor Relations Daniel Scavilla - President and Chief Executive Officer Keith Pfeil - Chief Operating Officer and Chief Financial Officer Conference Call Participants Matt Blackman - Stifel Matt Taylor - Jefferies Ryan Zimmerman - BTIG Steve Lichtman - Oppenheimer & Company Craig Bijou - Bank of America Securities Caitlin Cronin - Can ...

For the quarter ended March 2024, Globus Medical (GMED) reported revenue of $606.67 million, up 119.3% over the same period last year. EPS came in at $0.72, compared to $0.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $586.66 million, representing a surprise of +3.41%. The company delivered an EPS surprise of +30.91%, with the consensus EPS estimate being $0.55.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Globus Medical (GMED) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.91%. A quarter ago, it was expected that this medical device company would post earnings of $0.59 per share when it actually produced earnings of $0.60, delivering a surprise of 1.69%.Over the last four quarters, ...

or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2560 Gene ...

Globus Medical Reports First Quarter 2024 Results AUDUBON, PA, May 7, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. "Since the NuVasive merger closed in September of last year, we worked aggressively to execute our integration strategy and are making significant progress towards rapidly reaching steady state. I am pleased with the first quarter results delivered by strong teamwork and partners ...

Wall Street analysts expect Globus Medical (GMED) to post quarterly earnings of $0.55 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $586.66 million, up 112% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announces its earnings, it is essential to ...